FIELD: biotechnology.
SUBSTANCE: invention relates to a human AMHRII binding agent, its use in the prevention or treatment of lung cancer, and specifically non-small cell lung cancer (NSCLC), and even more specifically an NSCLC selected from the group consisting of epidermoid non-small cell lung cancer. The use of a human AMHRII binding agent as an active ingredient for the prevention or treatment of lung cancer in a patient selected from epidermoid non-small cell lung cancer (NSCLC), adenocarcinoma NSCLC, large cell NSCLC, squamous cell carcinoma NSCLC, pleomorphic carcinoma NSCLC and neuroendocrine NSCLC is proposed. The said agent comprises an anti-AMHRII monoclonal antibody or an AMHRII-binding fragment thereof. Also a method for determining the sensitivity of an individual suffering from NSCLC to cancer treatment with the said human AMHRII binding agent is provided. The method includes the step of determining whether the tumor tissue sample previously obtained from the specified individual expresses the AMHRII protein on the cell surface, and the individual is sensitive to cancer treatment with the specified agent, if it is determined that the tumor tissue sample demonstrates the presence of AMHRII expression on the cell surface.
EFFECT: invention provides additional tools for the treatment of non-small cell lung cancer.
7 cl, 21 dwg, 12 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMHRII BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCER | 2018 |
|
RU2816523C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
